ArticleFrontiers in microbiology2019
Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid.
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Therapeutic Use ofAnimals : an open access journal from MDPI · 2025Article
- Flavivirus infections and diagnostic challenges for dengue, West Nile and Zika Viruses.Npj viruses · 2025Review
- Article
- Reverse Genetics of Zika Virus Using a Bacterial Artificial Chromosome.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Identification and characterization of aurintricarboxylic acid as a potential inhibitor of SARS-CoV-2 PLpro.International journal of biological macromolecules · 2023Article
- Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection.Antimicrobial agents and chemotherapy · 2022Article
- Small Molecule Receptor Binding Inhibitors with In Vivo Efficacy against Botulinum Neurotoxin Serotypes A and E.International journal of molecular sciences · 2021Article
- Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease.The Biochemical journal · 2021Article
- Article
- Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.Molecules (Basel, Switzerland) · 2021Article
- Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.Journal of virological methods · 2021Article
- The Dual Regulation of Apoptosis by Flavivirus.Frontiers in microbiology · 2021Review
- Inhibition of Orbivirus Replication by Aurintricarboxylic Acid.International journal of molecular sciences · 2020Article
- Identification of Inhibitors of ZIKV Replication.Viruses · 2020Article
- Article
- In vivo rescue of recombinant Zika virus from an infectious cDNA clone and its implications in vaccine development.Scientific reports · 2020Article
- Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator.Viruses · 2019Article
- Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go.Pharmaceuticals (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Zika virus (ZIKV) is one of the recently emerging vector-borne viruses in humans and is responsible for severe congenital abnormalities such as microcephaly in the Western Hemisphere. Currently, only a few vaccine candidates and therapeutic drugs are being developed for the treatment of ZIKV infections, and as of yet none are commercially available. The polyanionic aromatic compound aurintricarboxylic acid (ATA) has been shown to have a broad-spectrum antimicrobial and antiviral activity. In this study, we evaluated ATA as a potential antiviral drug against ZIKV replication. The antiviral activity of ATA against ZIKV replication
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.